Novavax Company Profile (NASDAQ:NVAX)

About Novavax

Novavax logoNovavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NVAX
  • CUSIP: 67000210
Key Metrics:
  • Previous Close: $1.52
  • 50 Day Moving Average: $3.44
  • 200 Day Moving Average: $5.64
  • 52-Week Range: $270,834,000.00 - $1.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.73
  • P/E Growth: 0.00
  • Market Cap: $411.67M
  • Outstanding Shares: 270,834,000
  • Beta: 1.48
  • Net Margins: -1,405.84%
  • Return on Equity: -112.45%
  • Return on Assets: -56.29%
  • Debt-to-Equity Ratio: 2.87%
  • Current Ratio: 5.13%
  • Quick Ratio: 5.13%
Additional Links:
Companies Related to Novavax:

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (?)
Ratings Breakdown: 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $7.02 (361.92% upside)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)
DateFirmActionRatingPrice TargetDetails
10/10/2016FBR & CoReiterated RatingOutperform$12.00View Rating Details
9/20/2016Chardan CapitalLower Price TargetNeutral$5.75 -> $1.50View Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17View Rating Details
9/16/2016Citigroup Inc.DowngradeBuy -> Neutral$12.00 -> $1.50View Rating Details
9/16/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
9/16/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$14.00 -> $1.00View Rating Details
9/16/2016Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details
9/16/2016WedbushDowngradeOutperform -> Neutral$14.00 -> $2.00View Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00View Rating Details
4/7/2015Janney Montgomery ScottReiterated Rating$12.00View Rating Details
2/12/2015GMP SecuritiesInitiated CoveragePositiveView Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Novavax (NASDAQ:NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novavax (NASDAQ:NVAX)
Current Year EPS Consensus Estimate: $-1.1 EPS
Next Year EPS Consensus Estimate: $-0.88 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.27)($0.13)($0.22)
Q2 20163($0.28)($0.13)($0.19)
Q3 20162($0.27)($0.24)($0.26)
Q4 20162($0.26)($0.24)($0.25)
Q1 20171($0.25)($0.25)($0.25)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.24)($0.24)($0.24)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 79.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Novavax (NASDAQ:NVAX)
News IconNovavax, Inc. (NASDAQ:NVAX) (NASDAQ:NVAX) - October 19 at 6:51 PM
News IconWhat Wall Street is saying about Novavax, Inc. (NASDAQ:NVAX) (NASDAQ:NVAX) - October 19 at 6:51 PM
News IconPenny Stock Making News: Investors Looking Closely at Novavax, Inc. (NASDAQ:NVAX) - Duncan Research (NASDAQ:NVAX) - October 18 at 11:50 AM
News IconBiotech Stocks Worth Chasing: Ariad Pharmaceuticals Inc. (ARIA), Novavax, Inc. (NVAX) - The Independent Republic (NASDAQ:NVAX) - October 18 at 11:50 AM
News IconTrading the Biotech News: Nektar Therapeutics (NASDAQ:NKTR), Novavax, Inc. (NASDAQ:NVAX) - The Voice Registrar (NASDAQ:NVAX) - October 18 at 11:50 AM
News IconActive Biotech Stock News: Novavax, Inc. (NVAX), Celldex Therapeutics, Inc. (CLDX) - The Independent Republic (NASDAQ:NVAX) - October 18 at 11:50 AM
News IconInvestor's Watch List: Novavax, Inc. (NASDAQ:NVAX) - Post Registrar (NASDAQ:NVAX) - October 18 at 11:50 AM
News IconNovavax, Inc. (NASDAQ:NVAX) , Ophthotech Corporation (NASDAQ:OPHT) (NASDAQ:NVAX) - October 14 at 6:16 PM logoTraders Watch list Novavax, Inc. (NASDAQ:NVAX), Emerson Electric Co. (NYSE:EMR) - Wall Street 24 (NASDAQ:NVAX) - October 14 at 9:46 AM
News IconScorching Hot Biotech Stocks Tape: Novavax, Inc. (NVAX), ContraVir Pharmaceuticals, Inc. (CTRV) - The Independent Republic (NASDAQ:NVAX) - October 14 at 9:46 AM logoStocks in Focus: WPX Energy, Inc. (WPX), Novavax, Inc. (NVAX), Netflix, Inc. (NFLX) (NASDAQ:NVAX) - October 12 at 11:53 AM logoFBR Remains Positive on Novavax, Inc. (NVAX); Here’s Why (NASDAQ:NVAX) - October 10 at 6:04 PM logoInvestors want to know why Novavax drug trial failed. They'll have to wait. (NASDAQ:NVAX) - October 10 at 6:04 PM
News IconStocks in Mix Momentum- Galectin Therapeutics (NASDAQ:GALT), Novavax, Inc. (NVAX), Neptune Technologies ... - Seneca Globe (NASDAQ:NVAX) - October 10 at 11:11 AM logo3 Notable Runners: Ford Motor Co. (F), Novavax, Inc. (NVAX), The Procter & Gamble Company (PG) - iStreetWire (NASDAQ:NVAX) - October 10 at 11:11 AM
News IconSmall Cap in Focus: A Closer Look at Novavax, Inc. (NASDAQ:NVAX) - Duncan Research (NASDAQ:NVAX) - October 10 at 11:11 AM
News IconTraders Limelight- Novavax, Inc.'s (NVAX) - Hot Stocks Point (NASDAQ:NVAX) - October 10 at 11:11 AM
News IconCan Novavax, Inc.(NASDAQ:NVAX) Make A Comeback? - Journal Transcript (NASDAQ:NVAX) - October 10 at 11:11 AM
News IconBlackBerry Ltd (NASDAQ:BBRY) & Novavax, Inc. (NASDAQ:NVAX) Stocks Buzz - Money News (NASDAQ:NVAX) - October 8 at 6:00 PM
News IconAnalysts Valuations For Two Stocks: Novavax, Inc. (NASDAQ:NVAX), Stillwater Mining Company (NYSE:SWC) - The Voice Registrar (NASDAQ:NVAX) - October 8 at 6:00 PM
News IconNovavax, Inc. (NASDAQ:NVAX) Quarterly Sales Review - Newburgh Press (NASDAQ:NVAX) - October 8 at 6:00 PM
News IconBiotech Stocks Worth Chasing: Novavax, Inc. (NVAX), Corbus Pharmaceuticals Holdings, Inc. (CRBP) - The Independent Republic (NASDAQ:NVAX) - October 7 at 6:13 PM
News IconWatch List Stock- Novavax, Inc.'s (NVAX) - Hot Stocks Point (NASDAQ:NVAX) - October 7 at 6:13 PM
News IconBiotech Stocks Worth Chasing: Novavax, Inc. (NVAX), Gilead Sciences Inc. (GILD) - The Independent Republic (NASDAQ:NVAX) - October 7 at 6:13 PM logoNovavax, Inc. Imploded and Lost 70% in September -- Is There Any Hope Left? (NASDAQ:NVAX) - October 7 at 3:16 PM
News IconNovavax Reschedules 4th Annual Investor and (NASDAQ:NVAX) - October 7 at 11:37 AM logoNovavax (NVAX) Reschedules Investor, Analyst Meeting; Wants to Finalize Resolve Trial Data (NASDAQ:NVAX) - October 7 at 11:37 AM logoStock Update (NASDAQ:NVAX): Novavax, Inc. Reschedules 4th Annual Investor and Analyst Meeting (NASDAQ:NVAX) - October 7 at 11:37 AM logoNovavax Reschedules 4th Annual Investor and Analyst Meeting (NASDAQ:NVAX) - October 7 at 11:37 AM logoNovavax Reschedules 4th Annual Investor and Analyst Meeting - (NASDAQ:NVAX) - October 7 at 11:37 AM logoBRIEF-Novavax reschedules 4th annual investor, analyst meeting (NASDAQ:NVAX) - October 7 at 9:07 AM logo3 Biotech Investing Lessons From Novavax's Huge Vaccine Flop (NASDAQ:NVAX) - October 6 at 9:45 AM
News IconNews review of 2 biotech stocks: Novavax, Inc. (NASDAQ:NVAX), PDL BioPharma, Inc. (NASDAQ:PDLI) - The Voice Registrar (NASDAQ:NVAX) - October 5 at 11:43 AM
News IconInsider-Buying News: Novavax Inc (NASDAQ:NVAX) - The Voice Registrar (NASDAQ:NVAX) - October 5 at 11:43 AM logoNovavax to Host 4th Annual Investor and Analyst Meeting (NASDAQ:NVAX) - October 4 at 6:06 PM logoNovavax to Host 4th Annual Investor and Analyst Meeting - (NASDAQ:NVAX) - October 4 at 6:06 PM
News IconNovavax, Inc.'s (NVAX): Active Stock of Friday - Hot Stocks Point (NASDAQ:NVAX) - October 4 at 11:14 AM
News IconBiotech Stocks Worth Chasing: Achillion Pharmaceuticals, Inc. (ACHN), Novavax, Inc. (NVAX) - The Independent Republic (NASDAQ:NVAX) - October 4 at 11:14 AM logoNovavax's Big Disappointment -- What's Next? (NASDAQ:NVAX) - October 3 at 9:18 AM logoInsider Buying Slows as Trading Windows Begin to Shut: Performance Sports, DURECT, Natus Medical, Novavax and More (NASDAQ:NVAX) - October 2 at 10:35 AM
News IconMichael A. Mcmanus, Jr. Buys 30000 Shares of Novavax Inc. (NVAX) Stock (NASDAQ:NVAX) - September 30 at 6:37 PM
News IconStock under Review - Novavax, Inc. (NASDAQ:NVAX) - Hot Stocks Point (NASDAQ:NVAX) - September 30 at 11:44 AM
News IconFinancial Watchlist of Novavax, Inc. (NASDAQ:NVAX) - Newburgh Press (NASDAQ:NVAX) - September 30 at 11:44 AM
News IconBiotech Stocks Worth Chasing: Novavax, Inc. (NVAX), Exelixis, Inc. (EXEL) - The Independent Republic (NASDAQ:NVAX) - September 29 at 6:26 PM
News IconQuarterly Financial Update for Novavax, Inc. (NASDAQ:NVAX) - Newburgh Press (NASDAQ:NVAX) - September 29 at 11:39 AM
News IconBiotech Stocks Worth a Closer Look: Novavax, Inc. (NASDAQ:NVAX), Array BioPharma Inc. (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:NVAX) - September 29 at 11:39 AM logoOne Biotech Crashes, the Other Skyrockets -- Here's Why (NASDAQ:NVAX) - September 29 at 11:39 AM logoVBI Vaccines Is In Line For Investment Reallocation Boost From Novavax's Failure In RSV (NASDAQ:NVAX) - September 28 at 11:32 AM
News IconNovavax, Inc. (NASDAQ:NVAX) Sale Analysis - Newburgh Press (NASDAQ:NVAX) - September 27 at 6:22 PM
News IconNovavax, Inc. (NASDAQ:NVAX) could surge as high as $17 - Newburgh Press (NASDAQ:NVAX) - September 27 at 6:22 PM


Novavax (NASDAQ:NVAX) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff